Over the last year, several drugs have either been developed or tested to treat coronavirus. Now there’s another new antiviral drug that’s showing some promise by demonstrating ability to stop SARS-CoV-2 transmission within 24 hour!

Molnupiravir an antiviral investigational drug administered orally is currently undergoing clinical trials.

Molnupiravir a ribonucleoside analog was first developed as preventative medicine in early 2000s has shown to work against many viruses that employ an RNA-dependent RNA polymerase, which SARS-CoV-2 also has. Molnupiravir doesn’t stop the virus from replicating, though; instead, the drug introduces errors into the virus’s RNA that are then replicated until it’s defunct.

In July 2020, Florida-based Ridgeback Biotherapeutics and US drug maker Merck & Co Inc. announced their partnership to advance development of Molnupiravir in Covid-19.

Merck is considering studying Molnupiravir as a preventive treatment, to be deployed after a person is exposed but before they’ve fallen ill. That would allow the drug to be deployed even more broadly in the fight against Covid. Should Merck succeed in demonstrating that Molnupiravir is effective and free of serious side effects, it could be a boon to the society, for many years to come.
During an animal study on ferrets, they tried to get coronavirus to spread, and it wouldn’t. So, while it’s a treatment designed to prevent hospitalizations and deaths; it also seems to prevent transmission.

With resources big enough for a trial, Merck launched Phase II/III trials with an aim to enroll almost 3,000 patients in the U.S., Colombia, Israel, Russia, and elsewhere. The company is  checking  constantly about the pace of recruitment of the study trial and hopes in sending safety efficacy data  to the FDA to get emergency use authorization or even full authorization in record time.

ADVANTAGES

It has been designed as an oral, unlike other treatments right now that are IVs which indicates it as a potential drug that could come before hospitalization and perhaps even prevent severe symptoms.
The drug can also be used for people who do not want to get a vaccine or don’t have the resources to get shots.
The drug is only used in the short term, twice-daily for five days.
It has shown promise against several RNA viruses, not just SARS-CoV-2, which would mean it could help governments prepare for the next pandemic.

In India, decision to conduct human clinical trials with a new promising antiviral drug, Molnupiravir that is said to block covid transmission will be taken by the strategic group of scientist from Council of Scientific and Industrial Research (CSIR).

Dr. Shekhar  Mande, Director General Council of Scientific and Industrial Research has suggested that “Like many other anti-flu drugs, Molnupiravir would also undergo clinical trials for testing in humans and they will apply to the drug regulator for approval.”

A previous study from India has also shown that whereas the SARS-CoV-2 virus can become resistant to Remdesivir, an injectable drug which showed promise in treating moderate Covid-19 disease, Molnupiravir may prove more effective in preventing drug resistance and emerge as a latest gamechanger for Covid-19 treatment.

“Even as the world cheers the progress being made on several vaccines to protect against the Covid-19 pandemic, there is great excitement now on Molnupiravir, a new anti-viral drug which according to latest research completely suppresses virus transmission within 24 hours.”

According to Mr. Yusuf Hamied Chairman of Cipla  Limited, Merck has come to India and given all the generics companies an open license to produce this drug. Cipla is planning to do so and get approval in India.

Reference: 

More News
2022 | How the pharma industry is shaping up for the future
News · 17/01/2022

Given the evolving on-ground situation and newer variant-led infections, the pandemic is far from over. In such a scenario, for businesses to stay relevant, we will need to be flexible and more adaptable to the changes that need to be embraced to keep core business growth drivers resilient.

READ MORE
2022 | Chemical & Renewable Energy Industry Outlook
News · 06/12/2021

As the chemical industry moves into 2022, strong demand for both commodity and specialty chemicals should keep prices robust throughout the year. The industry could face margin pressures amid raw material cost inflation, which will likely remain high through the first half of 2022.

READ MORE
China’s strategic power cuts & “green” Winter Olympics 2022
News · 05/12/2021

Blackouts and power cuts in the world’s second-largest economy have drawn attention to fuel supply problems that could complicate the country’s pandemic recovery.

READ MORE
FIEO urges govt to provide freight support to all exports including pharmaceuticals till March 2022
News · 22/11/2021

The Federation of Indian Export Organizations (FIEO), an apex body of Indian export promotion organizations, has urged the government to provide freight support to all exports including pharmaceuticals till 31st March 2022, as freight rates have skyrocketed and are likely to somber by March 2022.

READ MORE
World’s First Pig Kidney Transplant Into Human Successfully Completed
News · 02/11/2021

Science keeps winning! Scientists recently transplanted a pig’s kidney into a human being without immediate rejection by the immune system.

READ MORE
WHO approves first Malaria vaccine developed by GlaxoSmithKline for children
News · 02/11/2021

In a landmark announcement, the World Health Organization (WHO) has recommended the use of the first-ever malaria vaccine for children. WHO Director-General Tedros Adhanom Ghebreyesus endorsed the RTS,S/AS01 malaria or Mosquirix – a vaccine developed by British drugmaker GlaxoSmithKline (GSK).

READ MORE
Power squeeze curbs Chinese growth, leaves Europe in a gas bind
News · 02/11/2021

China’s power shortages hit growth in the world’s second-biggest economy, threatening more pain for global supply chains, while Europe’s gas squeeze looked set to continue as Russia’s Gazprom showed no sign of hiking exports to the region in October.

READ MORE
Generic Agrochemicals in India Poised for a Bonanza: 22 Molecules Coming Off Patent by 2030
News · 04/10/2021

The fact that 22 such molecules are going to come out of their patent period will substantially expand the offerings of the Indian companies to people at home and abroad alike and may help fetch extra revenue.

READ MORE
SARS-CoV-2 is not a direct food safety concern… Neither food nor food packaging is a pathway for the spread of COVID-19, says FAO
News · 04/10/2021

“Current data indicates that neither food nor food packaging is a pathway for the spread of viruses causing respiratory illnesses, including SARS-CoV-2,” according to a new guidance document from the United Nations’ Food and Agriculture Organization (FAO): “In other words, SARS-CoV-2 is not a direct food safety concern.”

READ MORE